期刊
MOLECULAR THERAPY-NUCLEIC ACIDS
卷 25, 期 -, 页码 696-707出版社
CELL PRESS
DOI: 10.1016/j.omtn.2021.08.014
关键词
-
资金
- European Union's Horizon 2020 Research and Innovation Programme [810685, 648124]
- VLAIO grant [HBC.2017.0542]
- FWO [G036727N, 1210120N]
- Flemish Research Foundation
- Centre for Advanced Light Microscopy at Ghent University (Belgium)
- FWO-SB grant [1S14318N, 1S62519N]
The study successfully demonstrated Cas9 RNP transfection in various cell types using VNB photoporation, including refractive cells and achieving high gene knock-out levels. Gene knock-out according to user-defined spatial patterns was shown in stem cells and T cells. VNB photoporation is a scalable and versatile intracellular delivery method with great promise for CRISPR-Cas9-mediated ex vivo engineering of cell therapy products.
The CRISPR-Cas9 technology represents a powerful tool for genome engineering in eukaryotic cells, advancing both fundamental research and therapeutic strategies. Despite the enormous potential of the technology, efficient and direct intracellular delivery of Cas9 ribonucleoprotein (RNP) complexes in target cells poses a significant hurdle, especially in refractive primary cells. In the present work, vapor nanobubble (VNB) photoporation was explored for Cas9 RNP transfection in a variety of cell types. Proof of concept was first demonstrated in H1299-EGFP cells, before proceeding to hard-to-transfect stem cells and T cells. Gene knock-out levels over 80% and up to 60% were obtained for H1299 cells and mesenchymal stem cells, respectively. In these cell types, the unique possibility of VNB photoporation to knock out genes according to user-defined spatial patterns was demonstrated as well. Next, effective targeting of the programmed cell death 1 receptor and Wiskott-Aldrich syndrome gene in primary human T cells was demonstrated, reaching gene knock-out levels of 25% and 34%, respectively. With a throughput of >200,000 T cells per second, VNB photoporation is a scalable and versatile intracellular delivery method that holds great promise for CRISPR-Cas9-mediated ex vivo engineering of cell therapy products.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据